• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients.

作者信息

Solera Javier T, Ierullo Matthew, Arbol Berta G, Mavandadnejad Faranak, Kurtesi Alexandra, Qi Freda, Hu Queenie, Gingras Anne-Claude, Ferreira Victor H, Humar Atul, Kumar Deepali

机构信息

Ajmera Transplant Centre, University Health Network, Toronto, MG5 2N2, ON Canada.

Ajmera Transplant Centre, University Health Network, Toronto, MG5 2N2, ON Canada.

出版信息

Lancet Infect Dis. 2023 Aug;23(8):e266-e267. doi: 10.1016/S1473-3099(23)00357-2. Epub 2023 Jun 20.

DOI:10.1016/S1473-3099(23)00357-2
PMID:37352879
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10281643/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db4/10281643/dc6152e67706/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db4/10281643/dc6152e67706/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db4/10281643/dc6152e67706/gr1_lrg.jpg

相似文献

1
Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients.针对免疫功能低下患者的奥密克戎亚变体的二价新冠mRNA疫苗。
Lancet Infect Dis. 2023 Aug;23(8):e266-e267. doi: 10.1016/S1473-3099(23)00357-2. Epub 2023 Jun 20.
2
Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.接种 COVID-19 mRNA 疫苗加强针对日本养老院队列中奥密克戎亚变种 BA.1 和 BA.5 的中和作用。
Vaccine. 2023 Mar 24;41(13):2234-2242. doi: 10.1016/j.vaccine.2023.02.068. Epub 2023 Feb 27.
3
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.免疫功能低下患者接种第四剂 SARS-CoV-2 mRNA 疫苗后对奥密克戎的中和抗体强调了需要额外加强针。
Front Immunol. 2023 Jan 27;14:1104124. doi: 10.3389/fimmu.2023.1104124. eCollection 2023.
4
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.二价 SARS-CoV-2 mRNA 疫苗提高中和广度并预防小鼠感染奥密克戎变异株 BA.5。
Nat Med. 2023 Jan;29(1):247-257. doi: 10.1038/s41591-022-02092-8. Epub 2022 Oct 20.
5
Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.在未感染和既往感染人群中，BNT162b2 加强针接种对 SARS-CoV-2 奥密克戎 BA.2、BA.3、BA.4 和 BA.5 亚变异株的刺突结合抗体的影响。
Vaccine. 2023 Jan 23;41(4):879-882. doi: 10.1016/j.vaccine.2022.12.049. Epub 2022 Dec 24.
6
SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.养老院居民接种二价 COVID-19 疫苗后对原始 SARS-CoV-2 株和奥密克戎 BA.1 和 BA.4/BA.5 变异株的 SARS-CoV-2 抗体反应 - 俄亥俄州和罗得岛，2022 年 9 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2023 Jan 27;72(4):100-106. doi: 10.15585/mmwr.mm7204a4.
7
Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines.重复接种 COVID-19 mRNA 疫苗后对 SARS-CoV-2 奥密克戎亚变种的交叉中和作用。
J Med Virol. 2023 Jan;95(1):e28268. doi: 10.1002/jmv.28268. Epub 2022 Nov 10.
8
Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.原型株和奥密克戎 RBD mRNA 疫苗对奥密克戎变异株中和效力。
Front Immunol. 2022 Jun 30;13:908478. doi: 10.3389/fimmu.2022.908478. eCollection 2022.
9
Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection.新出现的奥密克戎亚变体可逃避疫苗或BA.1/BA.2感染所引发的中和免疫。
J Med Virol. 2023 Feb;95(2):e28539. doi: 10.1002/jmv.28539.
10
Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice.异源奥密克戎适应疫苗作为二次加强针可促进小鼠针对奥密克戎及其亚谱系的中和抗体。
Emerg Microbes Infect. 2023 Dec;12(1):e2143283. doi: 10.1080/22221751.2022.2143283.

引用本文的文献

1
Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS-CoV-2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4 T-Cell Activity.既往感染奥密克戎的移植受者对SARS-CoV-2 JN.1的纵向固有免疫和异源适应性免疫反应：中和作用有限但CD4 T细胞活性强劲
Transpl Infect Dis. 2025 Jul 2;27(4):e70067. doi: 10.1111/tid.70067.
2
Protection efficacy of mRNA-based SARS-CoV-2 variant vaccine in non-human primates.基于mRNA的新型冠状病毒变异株疫苗在非人灵长类动物中的保护效力
Acta Pharm Sin B. 2025 Feb;15(2):934-946. doi: 10.1016/j.apsb.2024.12.003. Epub 2024 Dec 7.
3
Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV.
HIV感染者对SARS-CoV-2奥密克戎BA.4/5 mRNA加强针的长期免疫反应。
Commun Med (Lond). 2025 Mar 27;5(1):92. doi: 10.1038/s43856-025-00799-6.
4
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses.针对不同免疫功能低下状况个体的新型冠状病毒mRNA疫苗纵向免疫原性队列研究：免疫反应的异质性及奥密克戎适应性加强剂量的关键作用
EBioMedicine. 2025 Mar;113:105577. doi: 10.1016/j.ebiom.2025.105577. Epub 2025 Feb 4.
5
Comparison of immune responses to SARS-CoV-2 spike following Omicron infection or Omicron BA.4/5 vaccination in kidney transplant recipients.肾移植受者感染奥密克戎或接种奥密克戎BA.4/5疫苗后对SARS-CoV-2刺突蛋白免疫反应的比较。
Front Immunol. 2025 Jan 14;15:1476294. doi: 10.3389/fimmu.2024.1476294. eCollection 2024.
6
Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.肿瘤坏死因子抑制剂治疗的免疫介导炎症性疾病患者对第五剂二价SARS-CoV-2疫苗的体液和细胞反应：一项前瞻性队列研究
Lancet Reg Health Eur. 2024 Nov 15;48:101121. doi: 10.1016/j.lanepe.2024.101121. eCollection 2025 Jan.
7
Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients.序贯接种基于奥密克戎的疫苗后，实体器官移植受者中 XBB 亚系中和作用迅速减弱和恢复。
Clin Infect Dis. 2024 Sep 26;79(3):652-655. doi: 10.1093/cid/ciae279.
8
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.mRNA 疫苗接种后肾移植受者对 SARS-CoV-2 奥密克戎亚变种的中和抗体反应和细胞反应。
Sci Rep. 2024 May 28;14(1):12176. doi: 10.1038/s41598-024-63147-z.
9
Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination.接种疫苗后新冠病毒突破性感染的预测因素
Vaccines (Basel). 2023 Dec 28;12(1):36. doi: 10.3390/vaccines12010036.
10
Humoral antibody response following mRNA vaccines against SARS-CoV-2 in solid organ transplant recipients; a status after a fifth and bivalent vaccine dose.mRNA 疫苗接种后在实体器官移植受者中针对 SARS-CoV-2 的体液抗体反应；第五剂和二价疫苗接种后的现状。
Front Immunol. 2023 Nov 27;14:1270814. doi: 10.3389/fimmu.2023.1270814. eCollection 2023.